Search results for "Tatin"

showing 10 items of 700 documents

Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ova…

1995

Objective To determine if the somatostatin analog, octreotide, affects insulin and related peptides and, hence, androgen levels differently between polycystic ovary syndrome (PCOS) patients and controls. Design Prospective controlled trial. Setting Reproductive endocrinology clinic of our medical center. Patients Eleven women with PCOS and six matched ovulatory controls. Interventions Octreotide (100 μg) was administered subcutaneously in the midfollicular phase. Serum was obtained before and at 60, 120, 180, and 240 minutes after octreotide. Main Outcome Measures Fasting insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), T, androstenedion…

Adultmedicine.medical_specialtyAdolescentendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentOctreotideBiologyOctreotideInsulin-like growth factor-binding proteinInternal medicinemedicineHumansInsulinTestosteroneProspective StudiesInsulin-Like Growth Factor ITestosteronePancreatic hormoneInsulinAndrostenedioneObstetrics and GynecologyFastingLuteinizing HormoneAndrogenPolycystic ovaryInsulin-Like Growth Factor Binding ProteinsSomatostatinEndocrinologyReproductive Medicinebiology.proteinFemaleCarrier ProteinsPolycystic Ovary Syndromemedicine.drugFertility and Sterility
researchProduct

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 over 6 months.

1986

This study examined the effects of the long-acting selective mini somatostatin analogue (SMS) 201-995 in two acromegalic patients who were treated for 3 and 6 months, respectively. During treatment the mean growth hormone levels (25.3 and 20.8 ng/ml vs 5.9 and 10.6 ng/ml) and somatomedin C levels (6.2 and 6.2 IU/ml vs 3.3 and 3.8 IU/ml) decreased and the patients reported an improvement in their symptoms. The main side effect was an increase in stool fat excretion which did exceed the normal range (less than 7 g/day) in one patient. Five acromegalics who received 2 X 50 micrograms SMS 201-995/day for 5 days showed a significant increase of stool fat excretion (1.7 vs 3.5 g/day; p less than …

Adultmedicine.medical_specialtyLong term treatmentSide effectAntineoplastic AgentsOctreotideExcretionInternal medicineDrug DiscoveryAcromegalyMedicineHumansPituitary NeoplasmsGenetics (clinical)Glycated Hemoglobinbusiness.industryAdenoma AcidophilGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseSomatomedinCombined Modality TherapyLong-Term CareSomatostatin AnalogueSomatostatinEndocrinologyGrowth HormoneAcromegalyMolecular MedicineFemaleHemoglobinNeoplasm Recurrence LocalbusinessSomatostatinKlinische Wochenschrift
researchProduct

LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALY

1984

In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 inj…

Adultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPeptide hormoneOctreotideEatingSubcutaneous injectionInternal medicineAcromegalymedicineHumansInsulinAgedChemotherapyMealChemistryGeneral MedicineGlucose Tolerance TestMiddle AgedGlucagonmedicine.diseaseGrowth hormone secretionEndocrinologySomatostatinBasal (medicine)Growth HormoneAcromegalySomatostatinThe Lancet
researchProduct

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

2006

OBJECTIVE—The Treating to New Targets study showed that intensive lipid-lowering therapy with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by atorvastatin 10 mg/day in patients with stable coronary heart disease (CHD). The objective of our study was to investigate whether similar benefits of high-dose intensive atorvastatin therapy can be achieved in patients with CHD and diabetes. RESEARCH DESIGN AND METHODS—A total of 1,501 patients with diabetes and CHD, with LDL cholesterol levels of <130 mg/dl, were randomized to double-blind therapy with either atorvastatin 10 (n = 753) or 80 (n = 748) mg/day. Patients were followed for a median of 4.9 years…

Advanced and Specialized Nursingmedicine.medical_specialtyCholesterolbusiness.industryEndocrinology Diabetes and MetabolismAtorvastatinHazard ratiomedicine.diseasechemistry.chemical_compoundEndocrinologyBlood pressurechemistryInternal medicineDiabetes mellitusInternal MedicineClinical endpointCardiologyMedicinelipids (amino acids peptides and proteins)cardiovascular diseasesMyocardial infarctionAdverse effectbusinessmedicine.drugDiabetes Care
researchProduct

Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins

2009

Abstract CAD (charged aerosol detector) has recently become a new alternative detection system in HPLC. This detection approach was applied in a new HPLC method for the determination of three of the major statins used in clinical treatment—simvastatin, lovastatin and atorvastatin. The method was optimized and the influence of individual parameters on CAD response and sensitivity was carefully studied. Chromatography was performed on a Zorbax Eclipse XDB C18 (4.6 mm × 75 mm, 3.5 μm), using acetonitrile and formic acid 0.1% as mobile phase. The detection was performed using both CAD (20 pA range) and DAD (diode array detector—238 nm) simultaneously connected in series. In terms of linearity, …

AerosolsSimvastatinAccuracy and precisionChromatographyChemistryFormic acidDetectorAnalytical chemistryLinearityCADHigh-performance liquid chromatographyAnalytical Chemistrychemistry.chemical_compoundEquipment and SuppliesHeptanoic AcidsWide dynamic rangeAtorvastatinPyrrolesLovastatinHydroxymethylglutaryl-CoA Reductase InhibitorsQuantitative analysis (chemistry)Chromatography High Pressure LiquidTabletsTalanta
researchProduct

Effects of Aging on the Structure and Expression of NMDA Receptors of Somatostatin Expressing Neurons in the Mouse Hippocampus

2021

Changes in the physiology, neurochemistry and structure of neurons, particularly of their dendritic spines, are thought to be crucial players in age-related cognitive decline. One of the most studied brain structures affected by aging is the hippocampus, known to be involved in different essential cognitive processes. While the aging-associated quantitative changes in dendritic spines of hippocampal pyramidal cells have already been studied, the relationship between aging and the structural dynamics of hippocampal interneurons remains relatively unknown. Spines are not a frequent feature in cortical inhibitory neurons, but these postsynaptic structures are abundant in a subpopulation of som…

Agingnervous systemhippocampusCognitive NeuroscienceAging NeuroscienceNMDA – receptorNeurosciences. Biological psychiatry. NeuropsychiatryinterneuronsomatostatinspineRC321-571Original ResearchFrontiers in Aging Neuroscience
researchProduct

The rxr agonist bexarotene in combination with rosuvastatin inhibits angiotensin-ii induced abdominal aortic aneurysm formation in apoliprotein -e-kn…

2014

AgonistBexarotenemedicine.medical_specialtybusiness.industrymedicine.drug_classPharmacologyRetinoid X receptormedicine.diseaseAngiotensin IIAbdominal aortic aneurysmEndocrinologyInternal medicineKnockout mouseMedicineRosuvastatinCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Negative staining across holes: application to fibril and tubular structures.

2007

The negative staining technique, when used with holey carbon support films, presents superior imaging conditions than is the case when samples are adsorbed to continuous carbon films. A demonstration of this negative staining approach is presented, using ammonium molybdate in combination with trehalose, applied to several fibrillar and tubular samples. Fibrils formed from the amyloid-beta peptide and the protease inhibitor pepstain A spread very well unsupported across holes and the different polymorphic fibril forms can be readily assessed. However, tubular forms of amyloid-beta have a tendency to be flattened, due to surface tension forces prior to and during specimen drying. Sub-fibril a…

AmyloidMaterials scienceGeneral Physics and Astronomychemistry.chemical_elementFibrilNegative Stainingchemistry.chemical_compoundFerrihydriteMicroscopy Electron TransmissionStructural BiologyIron-Binding ProteinsPepstatinsAnimalsHumansNanotechnologyGeneral Materials ScienceAmmonium molybdateMolybdenumAmyloid beta-PeptidesProteinsTrehaloseCell BiologyDNATrehaloseNegative stainCarbonStainingRatsCrystallographyCarbon filmchemistryBiophysicsCollagenPeptidesCarbonMicron (Oxford, England : 1993)
researchProduct

Inhibition of Histone Deacetylase Activity in Human Endometrial Stromal Cells Promotes Extracellular Matrix Remodelling and Limits Embryo Invasion

2011

Invasion of the trophoblast into the maternal decidua is regulated by both the trophoectoderm and the endometrial stroma, and entails the action of tissue remodeling enzymes. Trophoblast invasion requires the action of metalloproteinases (MMPs) to degrade extracellular matrix (ECM) proteins and in turn, decidual cells express tissue inhibitors of MMPs (TIMPs). The balance between these promoting and restraining factors is a key event for the successful outcome of pregnancy. Gene expression is post-transcriptionally regulated by histone deacetylases (HDACs) that unpacks condensed chromatin activating gene expression. In this study we analyze the effect of histone acetylation on the expressio…

Anatomy and PhysiologyGene ExpressionHydroxamic AcidsEndometriumEndocrinologyPregnancyMolecular Cell BiologyCells Culturedreproductive and urinary physiologyRegulation of gene expressionMultidisciplinarybiologyQRObstetrics and GynecologyExtracellular MatrixChromatinCell biologyHistonemedicine.anatomical_structureMatrix Metalloproteinase 9embryonic structuresMatrix Metalloproteinase 2MedicineFemaleHistone deacetylase activityResearch Articlemedicine.drugAdultStromal cellScienceDown-RegulationGene Expression Regulation EnzymologicYoung AdultmedicineHumansEmbryo ImplantationBiologyTissue Inhibitor of Metalloproteinase-3Tissue Inhibitor of Metalloproteinase-1Reproductive SystemTrophoblastUrokinase-Type Plasminogen ActivatorMolecular biologyHistone Deacetylase InhibitorsTrichostatin AAcetylationbiology.proteinStromal CellsDevelopmental Biology
researchProduct

Statin-induced autoimmune myositis: a proposal of an “experience-based” diagnostic algorithm from the analysis of 69 patients

2023

AbstractStatin-induced autoimmune myositis (SIAM) represents a rare clinical entity that can be triggered by prolonged statin treatment. Its pathogenetic substrate consists of an autoimmune-mediated mechanism, evidenced by the detection of antibodies directed against the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR Ab), the target enzyme of statin therapies. To facilitate the diagnosis of nuanced SIAM clinical cases, the present study proposes an “experience-based” diagnostic algorithm for SIAM. We have analyzed the clinical data of 69 patients diagnosed with SIAM. Sixty-seven patients have been collected from the 55 available and complete case records regarding SIAM in the l…

Anti-HMGCR antibodyStatin-induced autoimmune myositis (SIAM).SIAM case reportEmergency MedicineInternal MedicineSIAM diagnostic algorithmMuscle biopsyInternal and Emergency Medicine
researchProduct